Breaking News, Financial News

Financial Reports: Gilead

Stribild, Complera/Eviplera drive growth

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Gilead 4Q13 4Q Revenues: $3.1 billion (+21%) 4Q Earnings: $791 million (+4%) FY Revenues: $11.2 billion (+15%) FY Earnings: $3.1 billion (+19%) Comments: Product sales rose 21% in 4Q to $3.0 billion, driven by Stribild (+409% to $204 million), and Complera/Eviplera (+122% to $262 million). Atripla sales rose 2% to $934 million. In FY13, Atripla sales were up 2% to $3.6 billion, while Stribild posted $539 million (+837%) and Complera/Eviplera had $809 million in revenues (+137%). Gilead&#821...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters